April 25th 2024
Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Avoidable Colorectal Cancer Deaths Hit Low Socioeconomic Areas Hardest
December 4th 2015Disparities in colorectal cancer deaths have had a significant impact on the national economy, with areas of low socioeconomic status experiencing the greatest losses, according to a study by researchers at the Centers for Disease Control and Prevention (CDC).
Onivyde FDA Approved to Treat Metastatic Pancreatic Cancer
October 22nd 2015The FDA has approved MM-398, branded as Onivyde (irinotecan liposome injection) in combination with 5-fluorouracil (5-FU) chemotherapy and leucovorin for patients with metastatic pancreatic cancer. The treatment follows prior administration of a gemcitabine-based regimen.
"Hotspots" Highlight Need for Targeted Efforts to Promote Colorectal Cancer Screening
July 8th 2015Researchers have identified three "hotspots" in the United States where progress on reducing death rates from colorectal cancer have lagged, shining a light on areas of the country where efforts to increase screening uptake and promote healthier lifestyles could make a big difference.
Susan Mazanec on Activation for Health Management
April 28th 2015Susan R. Mazanec, PhD, RN, AOCN, Research Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, discusses a study that examined activation for health management in colorectal cancer patients and their family caregivers during the transition to post-treatment survivorship.
What Is Lynch Syndrome and Why Is It Important?
April 28th 2015Lynch syndrome (LS) is a hereditary syndrome that causes a marked increased risk of colorectal and other cancers. It is inherited in an autosomal dominant pattern, which means that it is due to a mutation in one copy of a gene (in LS, a DNA mismatch repair gene).
"Welcome to the Walk-through Colon" and Other GI Navigation Success Stories
April 27th 2015Oncology nurse navigators are known for identifying gaps in cancer care, being proactive in setting goals to address them, and designing specific interventions that lead not only to better-and measurable-outcomes but also to increased patient satisfaction.
Carmela Hoefling on Understanding Pancreatic Cancer
April 14th 2015Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the findings of a project on pancreatic treatment, care, and risk factors.
High Fitness Level in Older Men Associated with Lower Risk of Some Cancers
March 27th 2015A new study has shown that men with a high fitness level in midlife are not only at a lower risk of developing lung and colorectal cancer, they're also at a lower risk of dying from cancer if they're diagnosed later in life.
NO STOMACH FOR CANCER: Founded by a Family, for the Empowerment of Families
March 13th 2015Karen Chelcun Schreiber was first touched by gastric cancer in 1982, when her mother Elaine died of the disease at age 52. She was impacted again in 2007 when her brother Greg was diagnosed with Stage IV gastric cancer. He was 56.
Carmela Hoefling, RN, Discusses the Challenges of Treating Patients with Pancreatic Cancer
March 13th 2015Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses some of the challenges that nurses face when treating patients who have been diagnosed with pancreatic cancer.
Less Frequent Dosing of Pancreatic Cancer Regimen Effective, Less Toxic
January 19th 2015Changing the administration schedule for gemcitabine plus nab-paclitaxel (Abraxane) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
Investigators Find Potential Genetic Clues to Disparities in Colon Cancer
January 13th 2015Researchers from the Case Comprehensive Cancer Center have discovered new gene mutations that are unique to colon cancer in African American patients, who have the highest incidence and death rate from the disease.
Vitamin D Demonstrates Multiple Benefits for Patients With mCRC
January 12th 2015Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment
Studies Forecast More CRC in Young Adults and Find Higher Mortality Among the Least Educated
November 20th 2014Findings from two studies are shining a light on demographic and socioeconomic factors impacting who will be diagnosed with colorectal cancer (CRC), who is more likely to die from it, and what preventive measures might make a difference.